Cynata Therapeutics (ASX: CYP)


Cynata Therapeutics (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus. www.cynata.com

ASX biotech stocks COVID-19 life science

ASX biotech stocks benefiting from the COVID-19 story

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks acr...
Cynata Therapeutics ASX CYP clinical trial COVID-19 ethics approval Cymerus mesenchymal stem cells MSCs

Cynata Therapeutics gets approval for clinical trial on COVID-19

Biotechnology company Cynata Therapeutics (ASX: CYP) intends to develop a treatment for COVID-19 by repurposing its Cymerus mesenchymal stem cel...
Cynata Therapeutics ASX CYP tax incentive refund COVID-19 infection mesenchymal stem cells

Cynata Therapeutics’ stem cells could potentially help treat severe COVID-19 symptoms

Cynata Therapeutics (ASX: CYP) revealed it is in “active discussions” with international pharmaceutical companies and other parties regarding us...
Cynata Therapeutics ASX CYP sepsis blood poisoning Cymerus mesenchymal stem cells regenerative medicine MSC

Cynata Therapeutics has positive pre-clinical results using Cymerus stem cell platform to treat sepsis

Pre-clinical studies using Cynata Therapeutics’ (ASX: CYP) Cymerus mesenchymal stem cells in a sepsis model have achieved positive results. I...
Cynata Therapeutics ASX CYP Fujifilm graft-versus-host disease GvHD mesenchymal stem cell MSC CYP-001

Fujifilm to commercialise Cynata Therapeutics’ mesenchymal stem cell technology

Following a successful phase one clinical trial, FUJIFILM Corporation (Fujifilm) has exercised its option to commercialise Cynata Therapeutics’ ...
Cynata Therapeutics ASX CYP Cymerus mesenchymal stem cells MSCs preclinical trial glioblastoma brain cancer melanoma

Cynata Therapeutics reveals more positive pre-clinical cancer trial results

Biotechnology company Cynata Therapeutics (ASX: CYP) has published encouraging results from its ongoing preclinical program using its proprietar...
Cynata Therapeutics ASX CYP Cymerus stem cell treatment phase 1 trial

Cynata Therapeutics looks to advance Cymerus stem cell treatment into phase 2 trials

Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has said that it has “met all clinical endpoints” in its phase 1 tria...
Cynata Therapeutics ASX CYP stem cells regenerative medicine positive efficacy data study Cymerus mesenchymal MSCs heart attack

Cynata study shows positive link between stem cells and cardiac function post-heart attack

Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has announced positive efficacy data from a study of its Cymerus mese...
Cynata Therapeutics ASX CYP phase two trial bone marrow graft vs host disease

Phase 2 bone marrow transplant drug trial on the horizon for Cynata Therapeutics

Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) may advance to a phase 2 clinical trial of a new stem cell...
Cynata Therapeutics ASX CYP coronary artery disease heart stem cell therapy research

Cynata includes coronary artery disease into existing stem cell therapy research platform

Regenerative medicine company Cynata Therapeutics (ASX: CYP) has partnered up with the University of New South Wales (UNSW) in a bid to develop ...
Cynata Therapeutics ASX CYP granted Notice of Allowance from European Patent Office

Cynata Therapeutics receives notice of allowance ahead of patent for stem cell platform

A patent covering a stem cell technology platform developed by Cynata Therapeutics (ASX: CYP) appears on the horizon, following the receipt of a...
Cynata Therapeutics ASX CYP Cymerus patent stem cell technology

Cynata Therapeutics finalises Cymerus patent to treat adverse reactions to cancer immunotherapy

Cynata Therapeutics (ASX: CYP) has wrapped up an IP Australia patent application for therapeutic use of its Cymerus stem cell technology in trea...
Cynata Therapeutics ASX CYP Orphan Drug Designation FDA graft versus host disease bone marrow

Cynata receives key FDA approval to progress GvHD drug candidate

For the second time in as many days, the US Food and Drug Administration (FDA) has granted important permission to an ASX-listed company in the ...
Cynata Therapeutics ASX CYP trial stem cells treating graft versus host disease

Cynata unveils promising results in treating graft versus host disease with stem cells

Cynata Therapeutics (ASX: CYP) has unveiled “excellent” data from its “world first” clinical trial using its stem cell product CYP-001 in treati...
Cynata Therapeutics ASX CYP Celularity Cymerus

Cynata finds synergy with US-based biotech developer

Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has signed a Memorandum of Understanding (MoU) with Celula...
Cynata Therapeutics ASX CYP clinical trial mesenchymal stem cells

Cynata Therapeutics advance to second cohort in stem cell trial

Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has received an encouraging early response from the clinical trials o...
Cynata Therapeutics CYP ASX clinical trial stem cell graft versus host disease

Cynata Therapeutics enrols first cohort for world first clinical trial

Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has enrolled its first cohort for its “world first” clinical trial of...